Xenon Pharmaceuticals Inc. XENE
Set alert
At close · Oct 30
After hours · Oct 30, 4:49 PM ET
- YTD
- -16.53%
- 1 year
- -12.33%
- Open
- 37.54
- Prev close
- 37.54
- Mkt cap
- 3.62B
- Vol
- 1.12M
- Avg vol
- 1.51M
- EPS
- -4.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 36.84
- High
- 38.12
- Forward P/E
- -7.92
- Beta
- 0.60
- Short ratio
- 2.61
- Inst. own
- 107.44%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 45.79
- 200-d avg
- 52.39
- 1y target
- 71.94
News
2 days ago globenewswire.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…
-
3 days ago benzinga.com
Xenon Pharmaceuticals Announces Its XEN1701 Surpasses Target Profile; Data Presented During International Association For The Study Of Pain 2026 World Congress On Pain
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for…
3 days ago globenewswire.com
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
XEN1701 achieved target profile, including desired Na V 1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic…
1 week ago globenewswire.com
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ:…
2 weeks ago zacks.com
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
2 weeks ago benzinga.com
Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call
Xenon Pharmaceuticals (NASDAQ:XENE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is…
3 weeks ago benzinga.com
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity…
3 weeks ago globenewswire.com
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
-
3 weeks ago benzinga.com
Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73
Guggenheim analyst Delma Caiati assumes Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $73.
1 month ago globenewswire.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…
1 month ago newsfilecorp.com
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company…
1 month ago marketbeat.com
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
Xenon Pharmaceuticals NASDAQ: XENE said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry…
1 month ago businesswire.com
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $XENE--XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law.
1 month ago prnewswire.com
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)
Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials…
1 month ago seekingalpha.com
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate
Azetukalner's focal-seizure application gives Xenon Pharmaceuticals Inc. a potential path to its first commercial revenues, subject to FDA approval. The psychiatry setback weakens expansion…
1 month ago globenewswire.com
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
1 month ago globenewswire.com
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular session. The market value of their outstanding shares is at $1.0 million. SkyAI (NASDAQ:SKYA) stock rose…
1 month ago proactiveinvestors.com
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause
Xenon Pharmaceuticals Inc. (XENE:NASDAQ) shares were down 30%, on Friday morning after the company voluntarily halted new enrollment in major depressive disorder and bipolar depression studies. The…
1 month ago zacks.com
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.
1 month ago benzinga.com
Dow Falls Over 200 Points; Xenon Pharmaceuticals Shares Plunge
U.S. stocks fell Friday as weak industrial data weighed; Dow slid 0.45%, materials lagged, energy rose, and European shares declined.
1 month ago benzinga.com
Xenon Stock Reaction Is Overblown: Analyst
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures.
1 month ago benzinga.com
Xenon Stock Reaction Is Overblown: Analyst
Xenon Pharmaceuticals submits an FDA application for azetukalner for seizures while voluntarily pausing enrollment in depression trials.
-
1 month ago benzinga.com
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $70
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $81 to $70.
1 month ago benzinga.com
US Stocks Mixed; Industrial Production Unchanged In August
U.S. stocks mixed Friday: Nasdaq and S&P 500 edged higher, Dow slipped. Oil rose; industrial production was flat, while GIPR and IMCC surged.
-
1 month ago benzinga.com
Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $71 to $55.
1 month ago schaeffersresearch.com
Stock Futures Mixed After Thursday's Rebound
Stock futures are mixed after last session's rebound, with several Fed officials scheduled to make remarks
1 month ago benzinga.com
This Netflix Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
Analysts downgraded Magna, Franklin BSP, and more revising price targets for several.
1 month ago benzinga.com
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.
-
1 month ago benzinga.com
Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $64
Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and lowers the price target from $69 to $64.
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. Alaunos Therapeutics (NASDAQ:TCRT)…
1 month ago benzinga.com
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 150 points on Friday.
1 month ago benzinga.com
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
-
1 month ago benzinga.com
Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold, Lowers Price Target to $46
Deutsche Bank analyst David Hoang downgrades Xenon Pharmaceuticals (NASDAQ:XENE) from Buy to Hold and lowers the price target from $90 to $46.
1 month ago barrons.com
Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.'
-
1 month ago benzinga.com
Market-Moving News for September 18th
TCRT: 69% | Alaunos Therapeutics On Thursday Filed Patent Application "Identification Of Neoantigen-Reactive T Cell Receptors" MEDS: 24% | DataMeds AI Settles Litigation Related To Outstanding Debt…
-
1 month ago benzinga.com
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $78 to $60.
-
1 month ago benzinga.com
Baird Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $90
Baird analyst Brian Skorney maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $97 to $90.
1 month ago benzinga.com
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.
1 month ago benzinga.com
Xenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's Why
Xenon Pharmaceuticals shares fell 25% after hours after pausing new patient enrollment in ongoing psychiatry clinical studies.
1 month ago seekingalpha.com
Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript
Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript
1 month ago benzinga.com
Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock…
-
1 month ago benzinga.com
Xenon Pharmaceuticals Announces Voluntarily Initiated A Temporary Pause Of Enrollment Of New Patients In Ongoing Psychiatry Studies Following Neuropsychiatric Adverse Events; Patients Currently Enrolled In The Ongoing Studies Remain Active
In addition, the Company announced today that it has implemented a voluntary pause on enrollment for new patients in its ongoing clinical studies in major depressive disorder (MDD) and bipolar…
-
1 month ago benzinga.com
Xenon Pharmaceuticals Says X-NOVA2 Enrollment Reaches ~80% Of Its Initial Target Of 450 Patients; Topline Data Readout Expected Q1 2027
X-NOVA2 enrollment has reached approximately 80% of its initial target of 450 patients, which is sufficiently powered to demonstrate a clinically meaningful change in the study’s primary endpoint of…
-
1 month ago benzinga.com
Xenon Pharmaceuticals Submits NDA For Azetukalner In Focal Seizures To FDA
New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectivelyEnrollment…
-
2 months ago benzinga.com
Xenon Pharmaceuticals To Present 6 Azetukalner Data Sets, Including Encore Oral Presentation Of Topline Phase 3 X-TOLE2 Results At European Epilepsy Congress, Taking Place September 5-9, 2026
Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results New poster will highlight the mechanistic characterization of azetukalner, including its…
-
2 months ago benzinga.com
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $81
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $82 to $81.
-
2 months ago benzinga.com
Xenon Pharmaceuticals Q2 EPS $(1.11) Beats $(1.15) Estimate
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.15) by 2.63 percent. This is a 3.74 percent decrease over losses of…
4 months ago benzinga.com
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahead of key epilepsy trial data.